Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Long noncoding RNA HIKER regulates erythropoiesis in Monge’s disease via CSNK2B
Priti Azad, … , Tariq M. Rana, Gabriel G. Haddad
Priti Azad, … , Tariq M. Rana, Gabriel G. Haddad
Published April 6, 2023
Citation Information: J Clin Invest. 2023;133(11):e165831. https://doi.org/10.1172/JCI165831.
View: Text | PDF
Research Article Genetics Hematology

Long noncoding RNA HIKER regulates erythropoiesis in Monge’s disease via CSNK2B

  • Text
  • PDF
Abstract

Excessive erythrocytosis (EE) is a major hallmark of patients suffering from chronic mountain sickness (CMS, also known as Monge’s disease) and is responsible for major morbidity and even mortality in early adulthood. We took advantage of unique populations, one living at high altitude (Peru) showing EE, with another population, at the same altitude and region, showing no evidence of EE (non-CMS). Through RNA-Seq, we identified and validated the function of a group of long noncoding RNAs (lncRNAs) that regulate erythropoiesis in Monge’s disease, but not in the non-CMS population. Among these lncRNAs is hypoxia induced kinase-mediated erythropoietic regulator (HIKER)/LINC02228, which we showed plays a critical role in erythropoiesis in CMS cells. Under hypoxia, HIKER modulated CSNK2B (the regulatory subunit of casein kinase 2). A downregulation of HIKER downregulated CSNK2B, remarkably reducing erythropoiesis; furthermore, an upregulation of CSNK2B on the background of HIKER downregulation rescued erythropoiesis defects. Pharmacologic inhibition of CSNK2B drastically reduced erythroid colonies, and knockdown of CSNK2B in zebrafish led to a defect in hemoglobinization. We conclude that HIKER regulates erythropoiesis in Monge’s disease and acts through at least one specific target, CSNK2B, a casein kinase.

Authors

Priti Azad, Dan Zhou, Hung-Chi Tu, Francisco C. Villafuerte, David Traver, Tariq M. Rana, Gabriel G. Haddad

×

Figure 5

CSNK2B plays an important role in regulating erythropoiesis at high altitude partially through GATA1.

Options: View larger image (or click on image) Download as PowerPoint
CSNK2B plays an important role in regulating erythropoiesis at high alti...
(A) CSNK2B KD in CMS decreases BFU-E, and CSNK2B OE in non-CMS increases BFU-E, suggesting its critical role in regulating erythropoiesis. **P < 0.001. (B) Effect of CK2 inhibitor on CMS cells. TBB decreases BFU-E colonies in CMS cells in a dose-dependent manner. *P < 0.05; **P < 0.001. (C) Effect of CK2 inhibitor on CMS cells. CX4945 decreases BFU-E colonies more drastically in the CMS cells in a dose-response manner. **P < 0.01; ***P < 0.001; ****P < 0.0001. (D) CSNK2B KD results in major expression changes of critical TFs. qPCR results confirm decreased expression of TAL1, KLF1, RUNX1, IKAROS, and GATA1. *P < 0.05; ***P < 0.001. (E) GATA1 expression levels were altered significantly by modulation of CSNK2B levels in CMS and non-CMS cells under hypoxia. Graph shows GATA1 expression as measured by qPCR in (a) CMS cells, (b) CMS cells with CSNK2B KD, (c) CMS cells treated with CK2 inhibitor, (d) non-CMS cells, and (e) non-CMS cells with CSNK2B-OE. *P < 0.05; **P < 0.01. (F) CSNK2B regulates erythropoietic response through GATA1. Graph shows the effect of CSNK2B and GATA1 modulation on colony-forming potential of CMS and non-CMS cells. GATA1 OE partially rescues the erythropoietic suppression caused by CSNK2B in CMS. Further, KD of GATA1 in non-CMS results in loss of excessive erythropoiesis caused by OE of CSNK2B. *P < 0.05; **P < 0.001. For all the experiments (colony-forming assays as well as qPCR), iPSC-derived CD34+ cells were used. n = 3 per group. For A–F, 1-way ANOVA was performed, followed by multiple comparisons by Tukey’s test. For D, t tests were performed for each comparison.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts